Multidrug Resistance Proteins in Gastrointestinal Stromal Tumors: Site-Dependent Expression and Initial Response to Imatinib

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Clinical Cancer Research

• Publication date

  2005-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-05-0710PMID 16278376
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression of multidrug-resistance-associated protein gene in human soft-tissue sarcomas

  2005cited by this paper
• The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.

  2005cited by this paper
• P-glycoprotein expression in soft-tissue sarcomas

  2005cited by this paper
• A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential

  2004cited by this paper
• Imatinib mesylate ( STI 571 ) is a substrate for the breast cancer resistance protein ( BCRP ) / ABCG 2 drug pump

  2004cited by this paper
• P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

  2004cited by this paper
• Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site

  2004cited by this paper
• Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro

  2004cited by this paper
• Pharmacokinetic Resistance to Imatinib Mesylate: Role of the ABC Drug Pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the Oral Bioavailability of Imatinib

  2004cited by this paper
• Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors.

  2004cited by this paper
• Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site

  2004cited by this paper
• High expression of both mutant and wild-type alleles of c-kit in gastrointestinal stromal tumors.

  2004cited by this paper
• Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

  2004cited by this paper
• High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML.

  2003cited by this paper
• Gastrointestinal Stromal Tumors with Internal Tandem Duplications in 3′ End of KIT Juxtamembrane Domain Occur Predominantly in Stomach and Generally Seem to Have a Favorable Course

  2003cited by this paper
• MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.

  2003cited by this paper
• KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin.

  2003cited by this paper
• Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors.

  2003cited by this paper
• Expression of multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue sarcomas analysed according to their histological type and grade.

  2003cited by this paper
• Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro.

  2003cited by this paper
• Contrast of Response to Dacarbazine, Mitomycin, Doxorubicin, and Cisplatin (DMAP) Plus GM-CSF Between Patients with Advanced Malignant Gastrointestinal Stromal Tumors and Patients with Other Advanced Leiomyosarcomas

  2002cited by this paper
• Length Analysis of Polymerase Chain Reaction Products: A Sensitive and Reliable Technique for the Detection of Mutations in KIT Exon 11 in Gastrointestinal Stromal Tumors

  2002cited by this paper
• Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.

  2002cited by this paper
• Diagnosis of gastrointestinal stromal tumors: A consensus approach.

  2002cited by this paper
• Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review.

  2002cited by this paper
• Reversal of P-glycoprotein mediated multidrug resistance by a newly synthesized 1,4-benzothiazipine derivative, JTV-519.

  2002cited by this paper
• Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.

  2002cited by this paper
• A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.

  2002cited by this paper
• KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.

  2001cited by this paper
• Effect of c-kit Mutation on Prognosis of Gastrointestinal Stromal Tumors

  2001cited by this paper
• Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.

  2001cited by this paper
• Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

  2001cited by this paper
• Gastrointestinal stromal tumor workshop.

  2001cited by this paper
• Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins.

  2000cited by this paper
• Immunohistochemical Spectrum of GISTs at Different Sites and Their Differential Diagnosis with a Reference to CD117 (KIT)

  2000cited by this paper
• Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.

  1999cited by this paper
• Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas.

  1999cited by this paper
• Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors.

  1999cited by this paper
• C‐kit Gene Abnormalities in Gastrointestinal Stromal Tumors (Tumors of Interstitial Cells of Cajal)

  1999cited by this paper
• Multidrug resistance phenotype in high grade soft tissue sarcoma

  1999cited by this paper
• KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors.

  1998cited by this paper
• Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

  1998cited by this paper
• Drug resistance in the treatment of sarcomas.

  1997cited by this paper
• Evaluation of newer prognostic markers for adult soft tissue sarcomas.

  1997cited by this paper
• Drug resistance in the treatment of sarcomas.

  1997cited by this paper
• Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome.

  1995cited by this paper
• Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells.

  1994cited by this paper
• Expression of MDR1 and GST-pi in human soft tissue sarcomas: relation to drug resistance and biological aggressiveness.

  1992cited by this paper

• The application development of nanoparticle-based drug delivery systems in combating drug resistance of lung cancer

  2026cites this paper
• Measuring Tumour Imatinib Concentrations in Gastrointestinal Stromal Tumours: Relevant or Redundant?

  2023cites this paper
• What Is the Significance of Lysosomal-Mediated Resistance to Imatinib?

  2023cites this paper
• Noncoding RNAs in Drug Resistance of Gastrointestinal Stromal Tumor

  2022cites this paper
• SPK1/S1P axis confers gastrointestinal stromal tumors (GISTs) resistance of imatinib

  2022cites this paper
• Sensitive Metabolites and Single Nuclear Polymorphisms of OCT1 on Imatinib Meyslate in Patients with Gastrointestinal Stromal Tumors (GISTs)

  2021cites this paper
• Liver and gastrointestinal cancers

  2020cites this paper
• New insights into the clinical management of advanced gastrointestinal stromal tumors

  2020cites this paper
• The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs

  2020cites this paper
• Quantitative Mass Spectrometry Imaging Reveals Mutation Status-independent Lack of Imatinib Penetration into Liver Metastases of Gastrointestinal Stromal Tumors

  2019cites this paper
• BCR-ABL Inhibitors as Sensitizing Agents for Cancer Chemotherapy

  2019cites this paper
• Quantitative Mass Spectrometry Imaging Reveals Mutation Status-independent Lack of Imatinib in Liver Metastases of Gastrointestinal Stromal Tumors

  2019cites this paper
• Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents.

  2017cites this paper
• Identification of a secondary mutation in the KIT kinase domain correlated with imatinib-resistance in a canine mast cell tumor.

  2017cites this paper
• Optimization of Western blotting analysis for the isolation and detection of membrane xenobiotic transporter ABCG2.

  2017influential citation
• Anticancer Effects of a New Aminosugar-conjugated Platinum Complex Agent Against Cisplatin-resistant Gastric Cancer.

  2016cites this paper
• The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations

  2015influential citation
• FAM96A is a novel pro‐apoptotic tumor suppressor in gastrointestinal stromal tumors

  2015cites this paper
• Can the assessment of ABCB1 gene expression predict its function in vitro?

  2015cites this paper
• ABCG2 Inhibitors: Will They Find Clinical Relevance?

  2015cites this paper
• From the Department of Molecular Medicine and Surgery Karolinska Institutet, Stockholm, Sweden NOVEL ASPECTS OF THE MOLECULAR BIOLOGY OF GASTROINTESTINAL STROMAL TUMORS

  2014cites this paper
• Intracellular concentration of the tyrosine kinase inhibitor imatinib in gastrointestinal stromal tumor cells

  2014cites this paper
• Novel aspects of the molecular biology of gastrointestinal stromal tumors

  2014cites this paper
• ABC-transportørenes kliniske betydning MED-3950 5.-årsoppgave - Profesjonsstudiet i medisin ved Universitetet i Tromsø

  2013cites this paper
• Establishment and characterization of novel cell lines and xenografts from patients with gastrointestinal stromal tumors.

  2013cites this paper
• Anti-cancer effects of newly developed chemotherapeutic agent, glycoconjugated palladium (II) complex, against cisplatin-resistant gastric cancer cells

  2013cites this paper
• Mechanisms of acquired resistance to targeted cancer therapies.

  2012cites this paper
• Major response to everolimus in melanoma with acquired imatinib resistance.

  2012cites this paper
• Combination therapy for gastrointestinal stromal tumors: evidence from recent clinical trials

  2011cites this paper
• Development and application of novel analytical methods for molecularly targeted cancer therapeutics

  2011cites this paper
• Drug Transporters and Imatinib Treatment: Implications for Clinical Practice

  2010cites this paper
• The pharmacogenetics of imatinib

  2010cites this paper
• Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor

  2010cites this paper
• A Phase II Study of Imatinib in Patients with Advanced Anaplastic Thyroid Cancer

  2010cites this paper
• Interaction of ABC multidrug transporters with anticancer protein kinase inhibitors: substrates and/or inhibitors?

  2009cites this paper
• Overview of the molecular bases of resistance to chemotherapy in liver and gastrointestinal tumours.

  2009cites this paper
• Relevance of multidrug resistance in the age of targeted therapy.

  2009cites this paper
• Importance and limitations of chemotherapy among the available treatments for gastrointestinal tumours.

  2009cites this paper
• Imatinib Mesylate (Gleevec®) and the Emergence of Chemotherapeuticss Drug-Resistant Mutations

  2008cites this paper
• Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib

  2008cites this paper
• Gastrointestinal stromal tumours (GIST): experience in two hospitals of Bogotá D.C., Colombia (ONCOLGroup study)

  2008cites this paper
• Optimizing imatinib mesylate treatment in gastrointestinal stromal tumors.

  2008cites this paper
• Drug Insight: gastrointestinal stromal tumors (GIST)—the solid tumor model for cancer-specific treatment

  2008cites this paper
• Prowling wolves in sheep's clothing: the search for tumor stem cells

  2008cites this paper
• Tumores del estroma gastrointestinal (GIST): experiencia en dos instituciones hospitalarias de Bogotá D.C., Colombia (estudio del ONCOLGroup) Gastrointestinal stromal tumours (GIST): experience in two hospitals of Bogotá D.C., Colombia (ONCOLGroup study)

  2008cites this paper
• [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].

  2008cites this paper
• Expression of P-glycoprotein and metallothionein in gastrointestinal stromal tumor and leiomyosarcomas. Clinical implications

  2008cites this paper
• Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment.

  2007cites this paper
• A Review of Resistance Patterns and Phenotypic Changes in Gastrointestinal Stromal Tumors Following Imatinib Mesylate Therapy

  2007cites this paper
• A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors

  2007cites this paper
• Future options for imatinib mesilate-resistant tumors

  2007cites this paper
• Reply to ‘Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels’ by Widmer et al.

  2007cites this paper
• c-Kit/PDGFRA Gene Status Alterations Possibly Related to Primary Imatinib Resistance in Gastrointestinal Stromal Tumors

  2007cites this paper
• ABCG2: determining its relevance in clinical drug resistance

  2007cites this paper
• Improved detection of KIT exon 11 duplications in formalin-fixed, paraffin-embedded gastrointestinal stromal tumors.

  2007cites this paper
• KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).

  2006cites this paper
• SP analysis may be used to identify cancer stem cell populations.

  2006cites this paper
• The Application of Clinical Genetics Dovepress Diagnostic Criteria, Specific Mutations, and Genetic Predisposition in Gastrointestinal Stromal Tumors

  year unknowncites this paper